• 1
    Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med. 1980; 69: 491497.
  • 2
    Chamberlain JS. Cachexia in cancer–zeroing in on myosin. N Engl J Med. 2004; 351: 21242125.
  • 3
    Llovera M, Garcia–Martinez C, Lopez–Soariano J, et al. Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Mol Cell Endocrinol. 1998; 142: 183189.
  • 4
    Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS. NF–kappaB–induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science. 2000; 289: 23632366.
  • 5
    Costelli P, Muscaritoli M, Bossola M, et al. Skeletal muscle wasting in tumor–bearing rates is associated with MyoD down-regulation. Int J Oncol. 2005; 26: 16631668.
  • 6
    Torelli GF, Meguid MM, Moldawer LL, et al. Use of recombinant human soluble TNF receptor in anorectic tumor–bearing rats. Am J Physiol. 1999; 277: R850R855.
  • 7
    Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med. 2004; 350: 21672179.
  • 8
    Sloan JA, Loprinzi CL, Laurie JA, et al. A simple stratification factor prognostic for survival in advanced cancer: the good/bad/uncertain index. J Clin Oncol. 2001; 19: 35393546.
  • 9
    Jatoi A, Egner J, Loprinzi CL, et al. Investigating the utility of serum cytokine measurements in a multi–institutional cancer anorexia/weight loss trial. Support Care Cancer. 2004; 12: 640644.
  • 10
    Ribaudo JM, Cella D, Hahn EA, et al. Re–validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire. Qual Life Res. 2000; 9: 11371146.
  • 11
    Sloan JA, Loprinzi CL, Kuross SA, et al. Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol. 1998; 16: 36623673.
  • 12
    Jatoi A, Rowland K, Loprinzi CL, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer–associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol. 2004; 22: 24692476.
  • 13
    Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer–associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol. 2002; 20: 567573.
  • 14
    Ramos EJ, Suzuki S, Marks D, et al. Cancer anorexia–cachexia syndrome: cytokines and neuropeptides. Curr Opin Clin Nutr Metab Care. 2004; 7: 427734.
  • 15
    Boula A, Voulgarelis M, Giannouli S, et al. Effect of cA2 anti–tumor necrosis factor–alpha antibody therapy on hematopoiesis of patients with myelodysplastic syndromes. Clin Cancer Res. 2006; 12: 30993108.
  • 16
    Pastor IJ, Laso FJ, Romero A, et al. –238 G>A polymorphism of tumor necrosis factor alpha gene (TNFA) is associated with alcoholic liver cirrhosis in alcoholic Spanish men. Alcohol Clin Exp Res. 2005; 29: 19281931.
  • 17
    Achrol AS, Pawlikowska L, McCulloch CE, et al. Tumor necrosis factor–alpha–238 G>A promoter polymorphism is associated with increased risk of new hemorrhage in the natural course of patients with brain arteriovenous malformations. Stroke. 2006; 37: 231234.